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Post hoc analysisblinded conversion, during which placebo patients switched to perampanel. Patients then
entered the open-label treatment.
Results: Of 1480 patients from the core studies, 143 were adolescents. Pooled adolescent
data from these core studies demonstrated median percent decreases in seizure frequency
for perampanel 8 mg (34.8%) and 12 mg (35.6%) were approximately twice that of placebo
(18.0%). Responder rates increased with perampanel 8 mg (40.9%) and 12 mg (45.0%) versus
placebo (22.2%). Adolescents receiving concomitant enzyme-inducing antiepileptic drugs
(AEDs) had smaller reductions in seizure frequency (8 mg:31.6%; 12 mg:26.8%) than those
taking non-inducing AEDs (8 mg:54.6%; 12 mg:52.7%). Relative to pre-perampanel baseline,
seizure frequency and responder rates during the extension (Weeks 1e52) improved with
perampanel. Most commonly reported adverse events in adolescents during the core
studies were dizziness (20.4%), somnolence (15.3%), aggression (8.2%), decreased appetite
(6.1%), and rhinitis (5.1%). Dizziness (13.2%), somnolence (11.6%), and aggression (6.6%)
most often led to perampanel interruption/dose adjustment during the extension.
Significance: Data demonstrated adjunctive perampanel treatment in adolescents with
drug-resistant partial seizures produced better seizure control versus placebo, sustained
seizure frequency improvements, and a generally favorable safety profile. Results were
comparable to the overall study population.
Clinical Trial Registration: clinicaltrials.gov Identifiers: Study 304: NCT00699972; 305:
NCT00699582; 306: NCT00700310; Study 307: NCT00735397.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/4.0/).1. Introduction
Therapeutic advances over the past 20 years have led to the
development of newer drugs for the treatment of epilepsy.
Physicians can now choose from a number of antiepileptic
drugs (AEDs), although many of these have unknown mech-
anisms of action.1,2 Approximately 50% of patients achieve
seizure control on their first AED.3 For those whose seizures
remain uncontrolled, further antiepileptic medications or
combination regimens are prescribed.3 Despite such attempts
tomanage uncontrolled seizures with poly-AED therapy, rates
of drug resistance remain high.1,4,5
One longitudinal study of 525 children, adolescents, and
adults with newly diagnosed epilepsy showed that 37% were
considered drug-resistant even after adjunctive antiepileptic
therapy.5 Similar rates of drug resistance (25%e30%) have
been found in pediatric-only populations.2 Treatment-
limiting adverse events (AEs) associated with antiepileptic
therapy are common in the pediatric population, occurring in
26% of patients in one study involving 216 children and ado-
lescents.6 Thus the availability of novel AEDs that are effective
and well tolerated in adolescents represents a significant
unmet need.
Perampanel, the first in a novel class of AEDs, is a selective,
noncompetitive AMPA-receptor antagonist.7 The AMPA-type
glutamate receptors, located largely on post-synaptic excit-
atory synapses in the central nervous system, bind glutamate
and are key modulators in the generation and spread of
epileptiform activity.8 Perampanel is approved in more than
40 countries, including the United States (US) and in the Eu-
ropean Union (EU), for adjunctive treatment of partial seizures
with or without secondarily generalized seizures, in patients
with epilepsy aged 12 years, and in Canada in patients aged18 years.9 Findings from several clinical studies demonstrate
that perampanel administered once daily in doses up to
12mg/day reduces partial seizure frequency (including simple
partial seizures (with and without motor signs, complex par-
tial [CP] seizures, and partial seizures with secondarily
generalized [SG] seizures).10e16 Perampanel was well tolerated
by most patients aged 12 years old, despite the incidence of
AEs being greater in patients treated with 8 mg/day or 12 mg/
day,10e12,15 highlighting that perampanel dosing should be
based on clinical response and tolerability in order to provide
adequate, individualized seizure control.
Here we report the results of an analysis in a subpopu-
lation of adolescents (aged 12e17 years) with drug-resistant
partial seizures, based on data from the perampanel clinical
study program that were submitted to several regulatory
agencies for approval of the drug. Data from the three phase
III core studies and the combined extension study are
pooled here to assess the efficacy, long-term safety, and
tolerability of adjunctive perampanel in the adolescent
population.2. Materials and methods
2.1. Registration, protocol approvals, and informed
consent
The three phase III core studies (study 304: NCT00699972; 305:
NCT00699582; 306: NCT00700310) were conducted between
April 2008 and January 2011 in more than 40 countries.10e12
Study 307 (NCT00735397) was a long-term extension of
studies 304, 305, and 306.13 All studies were compliant with
the Helsinki Declaration, European Medicines Agency
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appropriate. Study protocols, amendments, and informed
consents were reviewed by national regulatory authorities in
each country and by independent ethics committees or
institutional review boards for each site. Written informed
consent before participation was provided by the legal
guardians and written/verbal assent was provided by the
patients.
2.2. Study design
The three phase III core studies were randomized, double-
blind, placebo-controlled evaluations of adjunctive per-
ampanel in doses of 2 mg/day to 12 mg/day (Supplementary
Fig. 1). Each study consisted of a 6-week prerandomization
phase; a 19-week, double-blind treatment phase (six weeks of
titration followed by 13 weeks of maintenance); and four
weeks of follow-up or continuation in the extension study.
Study designs for all three core studies were identical except
for the perampanel dose. Studies 304 and 305 evaluated per-
ampanel 8 mg/day and 12 mg/day; study 306 evaluated daily
doses of 2 mg, 4 mg, and 8 mg. In all three studies, patients
entered the prerandomization phase and were assessed for
baseline seizure frequency and eligibility for the 19-week,
double-blind treatment phase. Inclusion and exclusion
criteria were similar for all studies and have been published
previously.10e12 Patients or caregivers maintained a daily
diary to document partial seizure frequency and seizure type
(simple partial seizures with/without motor signs, CP sei-
zures, and partial seizures with SG seizures).15 During the six-
week titration period, perampanel oral doses given before
bedtime were increased by 2 mg/day/week.10e12 All patients
initially took six tablets (one tablet of 2 mg perampanel plus
five tablets of placebo [perampanel groups] or six tablets of
placebo [placebo group]). For the 4-, 8-, and 12-mg groups, the
dose was increased (by replacing placebo tablets with
perampanel tablets) at weekly intervals in increments of 2 mg
until the appropriate randomized dose or intolerability was
reached.10e12 Investigators were permitted to reduce the dose
at their discretion for patients experiencing intolerable AEs,
but more than one 2-mg down-titration at a time was
discouraged. Up-titration was allowed in these patients if
tolerability later improved.12 During the 13-week treatment
period, patients continued on the dose achieved during titra-
tion. Patients also continued receiving their established
concomitant AEDs without modification. Those who dis-
continued treatment or did not enter the extension study had
a follow-up visit four weeks after the end of therapy.10e12
The extension study began with a 16-week, blinded con-
version period, followed by a planned 256-week, open-label
perampanel maintenance period and a four-week follow-up
phase. Patients entered the conversion period on the same
dose of perampanel they achieved at the end of the double-
blind treatment phase. For patients who received placebo or
<12 mg perampanel/day during the core studies, the dose of
perampanel was up-titrated. During the conversion period,
patients and investigators remained blinded to the treatment
received in the previous core study. To achieve this, all
patients continued to take six tablets of study medication
(2 mg perampanel or matching placebo), and the dose wasincreased (by replacing placebo tablets with perampanel tab-
lets) at biweekly intervals in increments of 2 mg until the
maximally tolerated dose (12 mg/day) was reached. During
the open-label maintenance period, patients remained on the
maximally tolerated dose of perampanel achieved during the
blinded conversion period, unless further dose titration for
tolerability and/or efficacy reasons was necessary. Dose
adjustments, discontinuations, or changes in concomitant
AEDs were permitted at the discretion of the investigators.13
2.3. Patients
Patients eligible for the core studies were 12 years of age,
with a diagnosis of partial seizures (simple partial with motor
signs, CP, or CP plus SG), in accordance with the 1981 Inter-
national League Against Epilepsy Classification of Epileptic
Seizures.17 Patients must have had uncontrolled partial
seizure, had 2 AED failures in the previous two years, and
have been taking a stable type and dose regimen of 1e3
AEDs.13 During the six-week prerandomization phase, eligible
patients must have had 5 partial seizures (2 per each
3-week period).10e12 Patients who completed the double-blind
treatment phase of a core study were eligible to participate in
the extension study.13
2.4. Endpoints
Demonstration of efficacy was the main objective of the core
studies. The percent change from baseline in seizure
frequency over a 28-day period in the double-blind treatment
phase was the primary efficacy endpoint in the United States
and other non-European Union (EU) countries. Responder
rate, defined as the proportion of patients experiencing a
50% reduction in seizure frequency per 28 days during the
maintenance period compared with baseline, with last-
observation-carried-forward (LOCF) imputation, was a key
secondary efficacy endpoint in the United States and in other
non-EU countries. It was the primary efficacy endpoint for the
EU, per regional guidelines. Another secondary efficacy
endpoint was the percent change from baseline in the
frequency of CP plus SG seizures per 28 days during the
double-blind treatment phase. Safety assessments included
treatment-emergent adverse events (TEAEs, as defined by the
Medical Dictionary for Regulatory Activities [MedDRA]),
withdrawals, clinical laboratory parameters, vital signs, elec-
trocardiographic (ECG) studies, physical and neurological
examinations, and photosensitivity and withdrawal ques-
tionnaire responses.10e12
Long-term safety and tolerability assessments of
perampanel for treatment of drug-resistant partial seizures
were the key goals of the extension study. Evaluation of the
maintenance of perampanel efficacy demonstrated in the core
studies was a secondary goal.13
2.5. Additional analyses
The pharmacokinetic properties of perampanel and the ef-
fects of concomitant AEDs that may alter perampanel meta-
bolism by inducing the hepatic cytochrome P450 enzyme
system (eg, carbamazepine, oxcarbazepine, and
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pooling data from the three core studies. Blood samples
obtained during the treatment phase were used to determine
the effects of concomitant AEDs on perampanel concentration
and clearance. Exposure-response models for continuous
efficacy variables were fitted by nonlinear mixed-effect
modeling (NONMEM). The probability of response and occur-
rence of AEs were analyzed by logistic regression.
2.6. Statistical analyses
Details of the statistical analyses used in the core studies and
the extension are reported elsewhere.10e13 In brief, efficacy
data were reported using the intent-to-treat (ITT) analysis set
for the combined core studies, and consisted of all patients
who received 1 dose of perampanel and had any seizure-
frequency data collected during the double-blind phase of
any of the studies. For the extension study, the ITT analysis
set was defined as all patientswho provided informed consent
for the extension study, received1 dose of perampanel in the
extension study, and had valid seizure data during the
perampanel treatment duration (core and/or extension). Per-
centage change in seizure frequency was analyzed using a
rank analysis of covariance (ANCOVA), and responder rate
was evaluated using a CochraneManteleHaenszel test. Safety
analyses were conducted using the safety analysis set, which
consisted of all patients who received 1 dose of perampanel
and had 1 post-dose safety assessment. For AE analyses in
the extension study, perampanel treatment duration was
defined as all exposure to perampanel in the core and exten-
sion studies.10e133. Results
3.1. Patients
Of the total study population (adults and adolescents 12
years of age), 1480 patients were randomized and treated, 143
of whom were adolescents between the ages of 12 and 17 at
enrollment; 98 of these patients were randomized to per-
ampanel, and 45 were randomized to placebo (Fig. 1). Of these
143 adolescent patients, 129 completed a core study, and 124
of these completers (96.1%) enrolled in the extension study.
Enrollment in the extension study began in October 2008, and
the cutoff date for the data reported here was December 2010.
The adolescent population for the extension study consisted
of 122 patients in the ITT analysis set and 121 in the safety
analysis set (Fig. 1).
The median age for adolescents in the core and extension
studies was 15 years at baseline. Most patients were being
treatedwithmultiple AEDs prior to study initiation. In the core
studies, 79% of those receiving perampanel and 89% of those
in the placebo group were taking two or three baseline AEDs.
In the extension study, 82% of patients in the safety analysis
set were taking two or three AEDs (Table 1). The maximum
daily dose of >8e12 mg/day perampanel was reached by the
majority (>90%) of patients in the extension study, and the
mean dose was similar for the adolescent and overall safety
analysis populations.3.2. Efficacy
3.2.1. Phase III core studies
The primary and secondary efficacy endpoint results in the
adolescent population were generally consistent with the
findings for the overall core study population.10e12,15 Pooled
data from the three core studies demonstrated that in ado-
lescents, the median percent decreases in seizure frequency
for perampanel 8 mg (34.8%, n ¼ 44) and 12 mg (35.6%, n ¼ 20)
were approximately twice that of placebo (18.0%, n ¼ 45). The
median percent change in seizure frequency for adolescents
randomized to the 4-mg or 2-mg dose was a 23.9% decrease
(n ¼ 13) and a 12.8% increase (n ¼ 21), respectively. Adolescent
patients receiving concomitant inducer AEDs (carbamaze-
pine, oxcarbazepine or phenytoin) showed smaller median
percent reductions in seizure frequency for 8mg, 12mg doses,
and placebo (31.6%, 26.8%, and 15.4%, respectively) compared
to adolescents receiving concomitant noninducer AEDs (8 mg:
54.6%; 12 mg: 52.7%; placebo: 18.0%). This difference was not
observed for patients randomized to 4 mg.
For the secondary endpoints, responder rates in the
adolescent patient groups were 4.8% for perampanel 2 mg
(study 306), 23.1% for 4 mg (study 306), 40.9% for 8 mg (all
studies), 45.0% for 12 mg (studies 304 and 305), and 22.2% for
placebo (all studies). The responder rate for adolescents was
similar to that for the overall population for the majority of
perampanel doses (20.6%, 28.5%, 35.3%, 35.0% for perampanel
2 mg, 4 mg, 8 mg, and 12 mg, respectively, and 19.3% for
placebo).10e12,15 In adolescent patients with CP plus SG
seizures, the median percent decreases from baseline in fre-
quency for these seizures were 42.9%, 40.3%, 39.2%, and 4.4%,
for perampanel 4 mg, 8 mg, and 12 mg, and placebo, respec-
tively. In the perampanel 2-mg group therewas a 17% increase
in CP plus SG seizure frequency compared with baseline.
3.2.2. Extension study
Fig. 2 shows the median percent reduction in seizure
frequency and the responder rate in the adolescent popula-
tion on perampanel treatment during the core and extension
studies (Weeks 1e52). The median percent reduction in
seizure frequency relative to pre-perampanel baseline was
comparable between the adolescent and overall populations
(Fig. 2A). By the end of the 16-week conversion period of the
extension study, the median percent decrease in seizure
frequency relative to the double-blind prerandomization
baseline for adolescents switched from placebo to per-
ampanel was 35.8%; it was 40.9% in adolescents treated with
perampanel in both the core and extension studies. For ado-
lescents receiving placebo during the core studies, themedian
percent reduction in seizure frequency from the double-blind
prerandomization baseline ranged from 30.7% to 56.9% during
the first 52 weeks of the open-label maintenance period with
perampanel treatment. This rangewas similar for adolescents
who received perampanel during both the core and extension
studies (43.9%e61.1%). As shown in Fig. 2B, responder rates for
adolescents treated with perampanel during core and open-
label maintenance were not different from that of the over-
all population, demonstrating the efficacy of perampanel in
reducing seizure frequency. During the first 52 weeks of the
open-label maintenance period, responder rates ranged from
Fig. 1 e Adolescent patient disposition in the three core studies and the extension study. DB¼ double-blind; ITT¼ intent to
treat.
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the core studies who switched to perampanel during the
extension, and from 40.9% to 54.8% in adolescents receiving
perampanel throughout the study (core and extension).
In adolescent patients with CP plus SG seizures and those
with SG seizures only, there was a reduction in median
seizure frequency rate relative to prerandomization baseline
during the open-label maintenance period (Fig. 3A). In addi-
tion, responder rates ranged from 35.5% to 44.9% in patients
with CP plus SG, and 48.1% to 63.9% in patients with SG only
(Fig. 3B). Improvement in seizure frequency with perampanel,
as determined by seizure frequency and responder rates, was
greatest in patients with SG only during the open-label
maintenance period. This trend was similar to that
observed in the overall population for median percent change
in seizure frequency (CP þ SG, 32.2%e51.3%; SG, 55.0%e
85.5%) and responder rates (CP þ SG, 35.0%e50.8%; SG,
54.4%e69.6%).
3.3. Safety
3.3.1. Phase III core studies
During the double-blind treatment phase of the three core
studies, TEAEs occurred in 71.4% (n ¼ 70) and 68.9% (n ¼ 31) of
adolescent patients in the perampanel and placebo groups,
respectively (Supplementary Table 1). Adolescents dis-
continued treatment as a result of TEAEs at a rate of 2.0%
(n¼ 2) in the perampanel group and 6.7% (n¼ 3) in the placebo
group (Supplementary Table 1). Fifteen of 98 adolescentpatients (15.3%) in the perampanel group experienced TEAEs
requiring dose reduction or treatment interruption. None of
the 45 adolescent patients in the placebo group reduced their
dose or interrupted treatment because of TEAEs
(Supplementary Table 1). Serious AEs (SAEs) that occurred in
the perampanel group were aggression (2 mg, n ¼ 1; 12 mg,
n¼ 1) and ovarianmass/rupture (12mg, n¼ 1). Three placebo-
treated patients had SAEs (status epilepticus, n ¼ 1; convul-
sion, n ¼ 1; traumatic brain injury, n ¼ 1).
The most commonly reported TEAEs (>5% in perampanel-
treated patients and 2 times more often than with placebo)
during the double-blind phase were dizziness (20.4%, n ¼ 20),
somnolence (15.3%, n¼ 15), aggression (8.2%, n¼ 8), decreased
appetite (6.1%, n ¼ 6), and rhinitis (5.1%, n ¼ 5). The incidence
rates for these TEAEs differed for each perampanel dose
(Fig. 4). Comparedwith the overall population of patients from
the three core studies,10e12 aggression was reported more
frequently in the adolescent-only group (total perampanel vs
placebo: adolescents, 8.2% vs 0%; overall, 1.6% vs 0.5%), and
rates increased with higher doses. Of the eight adolescents in
whom aggression was reported, two experienced events that
were defined as SAEs (1 moderate, 1 severe), four required
drug interruption or adjustment, and one discontinued the
study as a result. These patients were described as having
either aggressive behavior, temper tantrums, behavioral
aggression or increased aggressive behavior.
There were no clinically significant changes from baseline
in clinical laboratory values, vital signs, ECG parameters, or
photosensitivity for adolescent patients in the perampanel
Table 1 e Demographic and clinical characteristics of adolescents (safety analysis set).
Characteristic Pooled data from three core studies Extension study
Placebo
(N ¼ 45)
Perampanel daily dose Perampanel daily dose
2 mg (N ¼ 21) 4 mg (N ¼ 13) 8 mg (N ¼ 44) 12 mg (N ¼ 20) Total (N ¼ 98) >4e8 mg (N ¼ 9) >8e12 mg (N ¼ 112) Total (N ¼ 121)
Median age, years (range) 15 (12e17) 15 (13e17) 16 (12e17) 16 (12e17) 15 (12e17) 15 (12e17) 15 (12e17) 15 (12e17) 15 (12e17)
Age group, n (%)
12e13 years 14 (31.1) 6 (28.6) 5 (38.5) 11 (25.0) 4 (20.0) 26 (26.5) 1 (11.1) 31 (27.7) 32 (26.4)
14e15 years 19 (42.2) 5 (23.8) 1 (7.7) 9 (20.5) 10 (50.0) 25 (25.5) 4 (44.4) 34 (30.4) 38 (31.4)
16e17 years 12 (26.7) 10 (47.6) 7 (53.8) 24 (54.5) 6 (30.0) 47 (48.0) 4 (44.4) 47 (42.0) 51 (42.1)
Male, n (%) 29 (64.4) 9 (42.9) 9 (69.2) 26 (59.1) 11 (55.0) 55 (56.1) 7 (77.8) 64 (57.1) 71 (58.7)
Race, n (%)
White 38 (84.4) 18 (85.7) 10 (76.9) 36 (81.8) 16 (80.0) 80 (81.6) 9 (100) 91 (81.3) 100 (82.6)
Black/African American 2 (4.4) 0 0 0 1 (5.0) 1 (1.0) 0 3 (2.7) 3 (2.5)
Asian 2 (4.4) 3 (14.3) 3 (23.1) 4 (9.1) 1 (5.0) 11 (11.2) 0 13 (11.6) 13 (10.7)
American Indian/Alaska
Native
1 (2.2) 0 0 0 0 0 0 0 0
Other 2 (4.4) 0 0 4 (9.1) 2 (10.0) 6 (6.1) 0 5 (4.5) 5 (4.1)
Hispanic/Latino, n (%) 10 (22.2) 1 (4.8) 0 9 (20.5) 5 (25.0) 15 (15.3) 3 (33.3) 16 (14.3) 19 (15.7)
Median weight, kg (range) 55.4 (30.6, 91.6) 49.0 (35.0, 105.2) 50.0 (23.3, 75.5) 52.0 (34.0, 99.0) 62.8 (34.7, 104.5) 52.9 (23.3, 105.2) 58.0 (39.0, 83.3) 54.0 (23.3, 105.2) 54.0 (23.3, 105.2)
Median BMI, kg/m2 (range) 20.3 (14.0, 31.0) 19.5 (16.4, 38.6) 19.1 (12.1, 27.1) 19.7 (15.1, 38.7) 21.7 (16.2, 32.7) 20.3 (12.1, 38.7) 22.3 (16.7, 30.9) 20.2 (12.1, 38.7) 20.2 (12.1, 38.7)
Seizure type, n (%)
Simple partial without
motor signs
11 (24.4) 2 (9.5) 2 (15.4) 11 (25.0) 5 (25.0) 20 (20.4) 3 (33.3) 24 (21.4) 27 (22.3)
Simple partial with
motor signs
18 (40.0) 8 (38.1) 10 (76.9) 17 (38.6) 11 (55.0) 46 (46.9) 4 (44.4) 51 (45.5) 55 (45.5)
Complex partial 35 (77.8) 18 (85.7) 11 (84.6) 42 (95.5) 16 (80.0) 87 (88.8) 8 (88.9) 100 (89.3) 108 (89.3)
Partial with secondary
generalization
30 (66.7) 11 (52.4) 10 (76.9) 28 (63.6) 13 (65.0) 62 (63.3) 7 (77.8) 71 (63.4) 78 (64.5)
Concomitant AEDs, n (%)
1 AED 5 (11.1) 3 (14.3) 1 (7.7) 14 (31.8) 3 (15.0) 21 (21.4) 2 (22.2) 20 (17.9) 22 (18.2)
2 AEDs 23 (51.1) 11 (52.4) 6 (46.2) 15 (34.1) 11 (55.0) 43 (43.9) 4 (44.4) 50 (44.6) 54 (44.6)
3 AEDs 17 (37.8) 7 (33.3) 6 (46.2) 15 (34.1) 6 (30.0) 34 (34.7) 3 (33.3) 42 (37.5) 45 (37.2)
AED, antiepileptic drug; BMI, body mass index.
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Fig. 2 e Median percent change from pre-perampanel baseline in all partial seizure frequency (A) and responder rates
(B) during the core and extension studies in adolescent and overall populations. *Week 1 begins on the date of first dose of
perampanel treatment. The perampanel treatment duration runs from the first perampanel dose in the double-blind or
open-label study to the last perampanel dose in the open-label study, except for subjects with a gap in perampanel
exposure from the double-blind to the open-label study of >14 days, whose perampanel treatment duration is the
open-label exposure period.
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 1 9 ( 2 0 1 5 ) 4 3 5e4 4 5 441groups, and no deaths were reported in the adolescent
population during the core studies (Supplementary Table 1).
3.3.2. Extension study
All adolescent patients who entered the extension study were
treated with perampanel, and the most frequently reported
TEAEs during perampanel exposure (core and extension
studies) were dizziness, somnolence, nasopharyngitis,
aggression, headache, convulsion, and pyrexia (Table 2). The
incidence of nasopharyngitis, aggression, convulsion, and
pyrexia were at least two times higher in adolescents than in
the overall study population, while the rate of dizziness was
slightly lower (Table 2). The TEAEs most often requiring per-
ampanel interruption or dose adjustment were dizziness
(13.2%, n ¼ 16), somnolence (11.6%, n ¼ 14), aggression (6.6%,n ¼ 8), irritability (2.5%, n ¼ 3), asthenia, ataxia, convulsion,
and abnormal behavior (n ¼ 2; 1.7% for each). The rate of
discontinuation due to TEAEs in adolescents was 14.9%
(n ¼ 18). The rate of SAEs in adolescent patients during the
extension study was 14.0% (n ¼ 17) (Supplementary Table 2).
No deaths were reported among adolescent patients during
the extension study (Supplementary Table 2).
Treatment-emergent psychiatric and behavioral AEs of
interest during the extension study were evaluated in the
adolescent patients, and the most common were aggression
(18.2%, n ¼ 22), insomnia (6.6%, n ¼ 8), abnormal behavior
(4.1%, n ¼ 5), anxiety (4.1%, n ¼ 5), and anger (3.3%, n ¼ 4). Of
the 22 adolescent patients with treatment-emergent aggres-
sion (including those from the core study), 21 received higher
doses of perampanel (>8e12 mg). Aggression was assessed by
Fig. 3 e Median percent change from pre-perampanel baseline in seizure frequency per 28 days (A) and responder rates
(B) during the core and extension studies in the adolescent population with complex partial plus secondarily generalized
(CPþ SG) or SG seizures only. *Week 1 begins on the date of first dose of perampanel treatment. The perampanel treatment
duration runs from the first perampanel dose in the double-blind or open-label study to the last perampanel dose in the
open-label study, except for subjects with a gap in perampanel exposure from the double-blind to the open-label study of
>14 days, whose the perampanel treatment duration is the open-label exposure period.
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 1 9 ( 2 0 1 5 ) 4 3 5e4 4 5442the investigators to be possibly or probably related to treat-
ment in 20 of 22 patients (91%) and was rated as mild (n ¼ 9),
moderate (n ¼ 10), or severe (n ¼ 3). Two were considered as
SAEs, and 3 patients with aggression discontinued the study.
The patients were described by the investigator as being
aggressive or combative; having aggression, aggressive
behavior, aggressiveness, temper tantrums, behavioral
aggression, violent outburst, aggressive outbursts or
increased aggressive behavior. Of the 22 adolescent patients
with treatment-emergent aggression, 17 were males (77.3%),
and the majority experienced a single episode of aggression
(n ¼ 16, 72.7%). There was no apparent relationship betweenthe duration of perampanel treatment and the timing of the
initial aggression episode, nor was there any apparent corre-
lation between adolescent age and the episode of aggression.
3.4. Pharmacokinetic/pharmacodynamic analyses (core
studies)
The mean plasma perampanel concentrations in adolescents
were 57.4 ng/mL, 109.6 ng/mL, 277.1 ng/mL, and 278.0 ng/mL
for the 2-mg, 4-mg, 8-mg, and 12-mg doses, respectively.
Plasma concentrations of perampanel were lower in patients
who received concomitant cytochrome P450-inducer AEDs
Fig. 4 e Common treatment-emergent adverse events occurring in >5% of the pooled perampanel-treated group and at ≥2
times the rate in the placebo group during the double-blind study in the adolescent population.
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 1 9 ( 2 0 1 5 ) 4 3 5e4 4 5 443(carbamazepine, oxcarbazepine, or phenytoin [except for
phenytoin in the 2- and 12-mg dose groups, most likely due to
the small number of patients receiving coadministered
phenytoin]) compared with plasma concentrations associated
with concomitant noninducers (Supplementary Table 3). Of
the 74 patients examined for pharmacokinetics/pharmaco-
dynamics, 62.0%were on concomitant inducers. The apparent
clearance of perampanel increased (and subsequently expo-
sure decreased) by approximately threefold with concomitant
carbamazepine and twofold with concomitant oxcarbazepine.
Other concomitant AEDs did not affect perampanel clearance.
The predicted probabilities of response in the 2-mg, 4-mg, 8-
mg, and 12-mg groups increased as the mean perampanel
concentration at steady state increased. In addition, the
pharmacokinetic model suggests that the probability of the
most frequent AEs in adolescents was not shown to be
affected significantly by plasma concentrations ofTable 2 e Most common TEAEs (occurring in ≥10%) on
perampanel treatment in adolescents and the overall
study population who entered the extension study
(safety analysis set, core and extension studies).
MedDRA
preferred
term
Total adolescent
population
(N ¼ 121)
Overall
population
(N ¼ 1186)
Any TEAE, n (%) 107 (88.4) 1037 (87.4)
Dizziness 37 (30.6) 521 (43.9)
Somnolence 29 (24.0) 240 (20.2)
Nasopharyngitis 23 (19.0) 87 (7.3)
Aggression 22 (18.2) 53 (4.5)
Headache 20 (16.5) 198 (16.7)
Convulsion 14 (11.6) 65 (5.5)
Pyrexia 13 (10.7) 47 (4.0)
MedDRA, medical dictionary for regulatory activities; TEAE,
treatment-emergent adverse event.perampanel. Thus the pharmacokinetic/pharmacodynamic
profile of perampanel in adolescents is consistent with pre-
vious results from the overall patient population from the
phase III core studies.204. Discussion
This post hoc analysis of three phase III studies demonstrated
that adjunctive therapy with perampanel reduced seizure
frequency in adolescents aged 12e17 years with drug-
resistant partial seizures. Pooled data from the double-blind
treatment phase of the three core studies showed that me-
dian reductions in seizure frequency among adolescents
randomized to perampanel 8mg or 12mgwere approximately
twice that of placebo. Perampanel also improved seizure
control for patients with CP plus SG seizures. These findings
from the phase III core studies in adolescent patients
(approximately 10% of the overall study population) are
generally consistent with the efficacy of perampanel in the
overall study population, which consisted largely of
adults.10e12
A large majority of the adolescent patients who completed
the double-blind phase III core studies entered the extension
study (96.1%) and were included in the full ITT analyses. This
interim analysis of the extension study (year one) shows that
seizure control improved for adolescent patients who
switched from placebo to perampanel, with reductions in
seizure frequency during the long-term extension. Further-
more, seizure control was sustained for adolescent patients
from the core studies who continued on perampanel, and as
was observed in the core studies, improvements in seizure
control with perampanel in adolescent patients with partial
seizures continued during the extension study. In addition,
the improvement was similar to that for the overall popula-
tion, as perampanel was an effective treatment for adolescent
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 1 9 ( 2 0 1 5 ) 4 3 5e4 4 5444patients with partial seizures, CP plus SG, and SG seizures
only.
Somnolence and dizziness are among the most common
AEs reported when AEDs (eg, gabapentin, lamotrigine,
topiramate, tiagabine, oxcarbazepine, zonisamide, and leve-
tiracetam) are used as adjunctive treatment for drug-resistant
partial seizures.21 These were the most frequent TEAEs for
perampanel in this adolescent population, highlighting that
the AE profile of perampanel is similar to other AEDs. During
the extension study, dizziness, somnolence, aggression, and
irritability were the TEAEs most often requiring perampanel
treatment interruption or dose adjustment.
Psychiatric symptoms and behavioral disturbances are
also common clinical features of epilepsy.22 In this post hoc,
pooled analysis, eight adolescents (8.2%) treated with per-
ampanel, compared to none in the placebo group from the
three core studies experienced treatment-emergent aggres-
sion on perampanel. In patients who continued with the
extension study, 22 adolescents (18.2%), including those from
the core study, reported treatment-emergent aggression. The
rate of treatment-emergent aggression was greater in ado-
lescents than in the overall population, although the majority
of aggression-related AEs were considered mild or moderate.
As noted in studies of other AEDs in use today, these medi-
cations can increase the risk of aggressive behavior.2,23e27
Patients treated with perampanel and their caregivers need
to be aware of potential aggressive behavioral adverse re-
actions, especially during titration and at higher doses.
The half-life of perampanel is approximately 105 h, and
steady state is reached in about two to three weeks.28 The
pharmacokinetic/pharmacodynamic properties of perampanel
in adolescents were similar to results from the overall popula-
tion from the phase III studies.20 The pharmacokinetic/phar-
macodynamicanalysisalsodemonstrates that theproportionof
responders increaseswith theconcentrationofperampanel and
that there were no significant effects on the probability of
response with coadministration of any of the AEDs. Although
the incidence of TEAEs such as dizziness and somnolence was
greater for adolescent patients receiving higher perampanel
doses, the pharmacokineticmodel suggests that the probability
of themost frequentAEsoccurring inadolescents isnot affected
significantly by plasma concentrations of perampanel. Daily
doses above 8 mg/day show greater effectiveness in the ran-
domized controlled clinical studies, although some patients
werenotable to tolerate the12mg/daydose.Therefore, thedose
should be based on the patient's clinical response and tolera-
bility28 to provide individualized seizure control.
This is the first full report to describe the efficacy and safety
of perampanel treatment of drug-resistant partial seizures in
adolescents, and some potential study limitations may be
relevant. Data were pooled from three studies that were iden-
tical in design; however, doses in study 306 differed from those
in theother twostudies, and therewasconsiderablegeographic
variation in study center locations (not all countries allowed
enrollment by adolescent patients, and the same countries
were not included in each study). Furthermore, the number of
adolescent patients overall (N¼ 121 in the safety analysis set of
the extension study) was relatively small. Consequently,
country, region, and study differences are confounded, and
caution should be used when interpreting the data.5. Conclusions
Perampanel is the only approved AED that inhibits glutamate-
mediated excitatory neurotransmission as its primary mech-
anism of action.7,29 When given as once-daily adjunctive
treatment for drug-resistant partial seizures, in doses of up to
12 mg/day, perampanel provided improved and sustained
seizure control (for partial seizures, CP þ SG, and SG seizures)
and a generally favorable AE profile in adolescents. Moreover,
seizure improvement was achieved in patients previously
receiving placebo in the double-blind studies when they were
switched to perampanel during the open-label extension.
Improvement was sustained in patients receiving perampanel
in the double-blind studies who continued perampanel in the
open-label extension. These results weremaintained for up to
a year in an open-label setting, providing strong evidence for
the benefits of perampanel as it would be prescribed in clinical
practice. The incidence of aggression with perampanel treat-
ment was greater in the adolescent population compared to
the overall population, and patients treated with perampanel
and their caregivers need to be aware of the potential for
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